Clinical trial
Phase II Iressa & Carbo/Gem in NSCLC
NCT00264498 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00264498 |
|---|---|
| Title | Phase II Iressa & Carbo/Gem in NSCLC |
| Official title | A Randomized, Open-Label Phase II Study Of ZD1839 (IRESSA™) Versus Gemcitabine And Carboplatin In Chemotherapy-Naive Patients With Advanced (Stage IIIB OR IV) Non-Small Cell Lung Cancer And ECOG Performance Status 2 |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Gefitinib, Gemcitabine, Carboplatin |
| Enrollment | 38 |
| Start date | Oct 1, 2004 |
| Completion | Jun 1, 2008 |
| First posted | Dec 13, 2005 |
| Last update posted | Aug 3, 2009 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: